...in series A funding, a team of Mavupharma...
...grew out of the firm’s success with Mavupharma Inc....
...butter.Inipharm CEO Brian Farmer was CBO at Mavupharma...

...a few other targets we’re looking at.” One reason for that is Frazier’s exit from Mavupharma Inc....
...to the STING pathway that could be used in cancer immunotherapy. The firm first seeded Mavupharma...
...program was de-risked over time,” Estes said (see “Mavupharma Raises $20M” ). By early 2019, Mavupharma...

...The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that...
...unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma Inc.’s...
...disclose financial terms of the deal (see “Mavupharma Raises $20M Series A for STING” ). Mavupharma...

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...11 ). Mavupharma Inc., Kirkland, Wash. Allison Johnson ADU-S100 Aduro Biotech Inc. Bristol-Myers Squibb Co. Cirius Therapeutics Inc. Frazier Healthcare Partners IFM Therapeutics Inc. Mavupharma Inc. Nimbus...

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...pathway within the tumor microenvironment or virally infected tissue. Frazier's Bob Baltera told BioCentury that Mavupharma...